UPDATE: Incyte Licenses Two Microarray Patents to Merck | GenomeWeb

This story has been updated from a previous version.

NEW YORK, April 11 – Incyte Genomics said Wednesday it had licensed two patents to Merck that will allow the pharmaceutical company to manufacture microarrays using a patented non-PCR method for RNA amplification.

The patents, numbers 5,716,785 and 5,891,636, cover the use of a non-PCR-based RNA amplification technology, allowing researchers to create gene expression information by linearly increasing RNA samples from cellular mRNA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.